Travel Medicine Update

Icahn School of Medicine at Mount Sinai

D. Caplivski

Project 2025 vs. the Public's Health Part II: The FDA

MicrobeTV

P. Offit, V. Racaniello

Nirsevimab for RSV: A Breakthrough Product for Babies

MicrobeTV

P. Offit, V. Racaniello

Hydrocortisone Reduces Mortality by 48% in Severe Community-Acquired…

MedCram

R. Seheult

What to Know About the FDA Authorization and Approval of Updated COV…

Amesh Adalja

COVID 2024 Surge: The Most Accessible Defense

MedCram

R. Seheult

Preparing for Winter: CDC Recommendations for Influenza, COVID-19, a…

Diego Hijano

Project 2025 vs. the Public's Health Part III: The NIH

MicrobeTV

P. Offit, V. Racaniello

The Durability of the Antibody Response Following Monkeypox Vaccinat…

MicrobeTV

D. Griffin, V. Racaniello

CHEST 2024 Insights: Vaccination Challenges and Strategies for Viral…

CHEST Annual Meeting Insights

A. Kapoor

Understanding Changes in Acute Care and Mortality Patterns Among Chi…

Christina Belza

Newly Licensed Respiratory Syncytial Virus Vaccines for Adults: What…

MicrobeTV

P. Offit, V. Racaniello

CHEST Insights 2024: Determining the Impact of COVID-19 Infection on…

CHEST Annual Meeting Insights

A. Arumairaj

Preventing Complications with Vaccines in Persons with Diabetes (PWD)

Allison Presnell

IDSA Guidelines for Using Anti-SARS-CoV-2 Monoclonal Antibody Therap…

MicrobeTV

D. Griffin, V. Racaniello

H5N1 Outbreak: Are We Inching Closer to Human Transmissibility?

MedCram

R. Seheult

Project 2025 vs. The Public’s Health Part I: The CDC

MicrobeTV

P. Offit, V. Racaniello

Monkeypox Declared a Public Health Emergency of International Concer…

MicrobeTV

D. Griffin, V. Racaniello

Long COVID and ME/CFS: Are They the Same Condition?

Charles Shepherd

Durability of Protection Following Administration of Recombinant Ant…

MicrobeTV

D. Griffin, V. Racaniello